Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of tanshinone IIA or pharmaceutically acceptable salt thereof in improving exercise tolerance of pulmonary vascular disease patients

A vascular disease, tanshinone technology, applied in the new application field of tanshinone IIA, can solve the problems of limited activity, decreased activity tolerance, limited curative effect, etc., and achieves the effect of low price and improved activity tolerance

Inactive Publication Date: 2013-03-13
THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT) +1
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, symptoms such as shortness of breath, fatigue, dyspnea, limited activity, or decreased activity tolerance may occur, which will affect the patient's prognosis and quality of life.
At present, the treatment of pulmonary vessels is a difficult point clinically, and there are few types of drugs that can be used for pulmonary vessel treatment and their curative effects are limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tanshinone IIA or pharmaceutically acceptable salt thereof in improving exercise tolerance of pulmonary vascular disease patients
  • Application of tanshinone IIA or pharmaceutically acceptable salt thereof in improving exercise tolerance of pulmonary vascular disease patients
  • Application of tanshinone IIA or pharmaceutically acceptable salt thereof in improving exercise tolerance of pulmonary vascular disease patients

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1: Tanshinone IIA can significantly increase the average six-minute walking distance in patients with pulmonary arterial hypertension after four weeks of treatment

[0027] 1. Patient Information

[0028] There were 10 patients, including 4 males and 6 females, aged 17-62 years.

[0029] 2. Inclusion criteria

[0030] All patients enrolled in the group were diagnosed as patients with pulmonary arterial hypertension according to the "ESC2009 Guidelines for the Diagnosis, Treatment and Treatment of Pulmonary Hypertension".

[0031] 3. Experimental plan

[0032] After the patients were enrolled in the group, they performed a six-minute walk test (6MWT), recorded the average six-minute walk distance before the experiment, and then received conventional treatment according to their condition, and gave Tanshinone IIA Sodium Sulfonate Injection 1mg / Kg·body weight, plus 5% glucose injection Liquid, intravenous infusion, once a day, the treatment cycle is 4 we...

Embodiment 2

[0035] Example 2: Tanshinone IIA can significantly improve dyspnea and fatigue scores in patients with pulmonary arterial hypertension after four weeks of treatment

[0036] 1. Patient Information

[0037] There were 10 patients, including 4 males and 6 females, aged 17-62 years.

[0038] 2. Inclusion criteria

[0039] All patients enrolled in the group were diagnosed as patients with pulmonary arterial hypertension according to the "ESC2009 Guidelines for the Diagnosis, Treatment and Treatment of Pulmonary Hypertension".

[0040] 3. Experimental plan

[0041] After the patients were enrolled in the group, the patients were asked to use the Borg Dyspnea and Fatigue Scale to score their dyspnea and fatigue (Borg score), record the score before the experiment, and then receive routine treatment according to their condition, and give Tanshinone IIA Sodium Sulfonate Injection 1mg / Kg · body weight, plus 5% glucose injection, intravenous infusion, once a day, the treatme...

Embodiment 3

[0044] Example 3: Tanshinone IIA can significantly increase the average six-minute walking distance in patients with chronic thromboembolic pulmonary hypertension after four weeks of treatment

[0045] 1. Patient Information

[0046] There were 3 patients, all female, aged 46-62 years.

[0047] 2. Inclusion criteria

[0048] All patients enrolled in the group were diagnosed as patients with chronic thromboembolic pulmonary hypertension according to the "ESC2009 Guidelines for the Diagnosis, Treatment and Treatment of Pulmonary Hypertension".

[0049] 3. Experimental plan

[0050] After the patients were enrolled in the group, they performed a six-minute walk test (6MWT), recorded the average six-minute walk distance before the experiment, and then received conventional treatment according to their condition, and gave Tanshinone IIA Sodium Sulfonate Injection 1mg / Kg·body weight, plus 5% glucose injection Liquid, intravenous infusion, once a day, the treatment cycle i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of tanshinone IIA or a pharmaceutically acceptable salt thereof in preparing a medicament for improving the exercise tolerance of pulmonary vascular disease patients. The tanshinone IIA or the pharmaceutically acceptable salt thereof can be used for preparing the medicament for improving the exercise tolerance of the pulmonary vascular disease patients; the tanshinone IIA or the pharmaceutically acceptable salts thereof can be combined with common medicaments for treating the pulmonary vascular diseases clinically at present; and the tanshinone IIA or the pharmaceutically acceptable salt thereof is safe and effective and low in price, and has bright market prospect.

Description

technical field [0001] The present invention relates to a new application of tanshinone IIA, in particular to the application of tanshinone IIA or a pharmaceutically acceptable salt thereof in improving activity tolerance of patients with pulmonary vascular diseases. Background technique [0002] Salvia miltiorrhiza is the dry root and rhizome of Radix Salvia Miltiorrhiza bge., a plant of the Labiatae family. It was first recorded in "Shen Nong's Materia Medica". It is bitter in taste and slightly cold in nature. It is the top grade, Guixin and Liver classics, all of which have been recorded in successive dynasties of herbal medicine. [0003] Tanshinone Ⅱ A is an effective monomer extracted from the traditional Chinese medicine Danshen, and its molecular formula is C 19 h 18 o 3 At present, it is mainly used clinically in the treatment of cardiovascular diseases, and has the functions of anti-atherosclerosis, inhibition of left ventricular hypertrophy, and anti-arrhythmi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61P11/00A61P9/12
Inventor 王健陈豫钦卢文菊江倩
Owner THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com